Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
25 Oct 2024
// INDPHARMAPOST
https://www.indianpharmapost.com/news/syngene-international-posts-q2-fy25-consolidated-pat-at-rs-1061-cr-16361
25 Jul 2024
// INDIANPHARMAPOST
https://www.indianpharmapost.com/news/syngene-reports-drop-in-q1-fy25-revenue-to-rs-790-cr-15917
05 Jun 2024
// PHARMABIZ
04 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/syngene-launches-platform-for-rapid-enhanced-protein-production-302164024.html
24 Apr 2024
// INDINPHARMAPOST
https://www.indianpharmapost.com/news/syngene-international-reports-q4-fy24-consolidated-pat-at-rs-1886-cr-15564
11 Apr 2024
// MONEYCONTROL
https://www.moneycontrol.com/news/business/earnings/goldman-sach-initiates-buy-on-syngene-neuland-adds-sell-tag-to-larus-lab-12625281.html
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Date of Issue : 2021-07-14
Valid Till : 2024-07-13
Written Confirmation Number : WC-0502
Address of the Firm :
Date of Issue : 2021-07-14
Valid Till : 2024-07-13
Written Confirmation Number : WC-0502
Address of the Firm : Biocon Park, Plot No 2,3,4, Un...
NDC Package Code : 84101-001
Start Marketing Date : 2024-02-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PR...
Details:
VXA-CoV2-1, an oral tablet COVID-19 vaccine triggers mucosal immune responses in humans, is believed to be the first defense against airborne viruses, such as coronavirus and flu.
Lead Product(s): VXA-CoV2-1.1-S
Therapeutic Area: Infections and Infectious Diseases Brand Name: VXA-CoV2-1.1-S
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Vaxart
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Lead Product(s) : VXA-CoV2-1.1-S
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Vaxart
Deal Size : Not Applicable
Deal Type : Not Applicable
Syngene Set For Phase-2 Trial Of Covid Oral Tablet Vaccine
Details : VXA-CoV2-1, an oral tablet COVID-19 vaccine triggers mucosal immune responses in humans, is believed to be the first defense against airborne viruses, such as coronavirus and flu.
Brand Name : VXA-CoV2-1.1-S
Molecule Type : Vaccine
Upfront Cash : Not Applicable
October 11, 2022
Details:
The collaboration has been extended through the end of 2030 and will expand the breadth of drug discovery research conducted, including chemistry, biology, drug metabolism and pharmacokinetics, as well as translational medicine research and pharmaceutical development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 26, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration has been extended through the end of 2030 and will expand the breadth of drug discovery research conducted, including chemistry, biology, drug metabolism and pharmacokinetics, as well as translational medicine research and pharmaceutica...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
April 26, 2021
Services
Analytical
Inspections and registrations
ABOUT THIS PAGE
Syngene International Limited is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Odevixibat bulk offered by Syngene International Limited
LOOKING FOR A SUPPLIER?